Table 3.
Induction of HLA-A*02–restricted, HER-2/neu–specific T cells by allogeneic KS24.22 breast cancer cells in vitro
| Stimulus in MLTC | Target antigen in ELISpotb | Frequencies of IFN-γ–secreting T cells in 100,000 or 500,000 effector cellsa | ||
|---|---|---|---|---|
| Day 28 | Day 14 | Day 0 (ex vivo) | ||
| KS24.22/MP58-66 | MP58-66 | 1,800/100,000c | 700/100,000 | 56/100,000 |
| KS24.22 | HER-2/neu369-377 | 0/500,000 | 0/500,000 | 0/500,000 |
| KS24.22 | HER-2/neu654-662 | 40/500,000 | 0/500,000 | 0/500,000 |
| KS24.22 | HER-2/neu1023-1032 | 72/500,000 | 0/500,000 | 0/500,000 |
aT cells of a HLA-A*0201+ breast cancer patient were stimulated weekly using either unpulsed or MP58-66-pulsed IFN-γ–pretreated KS24.22 cells. Frequencies of MP58-66-specific or HER-2/neu–specific T cells were determined by IFN-γ ELISpot ex vivo (without stimulation), on day 14, and day 28 (T cells in different MLTC)
bAntigen-specificity was determined using T2 cells loaded with HLA-A*0201–restricted epitopes of either MP or HER-2/neu
cNumber of antigen-specific T cells per 100,000 and 500,000 plated effector cells, respectively. T cells responding to the control peptide p68 are subtracted from T cells reactive to the antigens of interest